Exiqon Q2 Revenues Shrink 8 Percent | GenomeWeb

NEW YORK (GenomeWeb) – Danish miRNA biomarker firm Exiqon reported today an 8 percent decrease year over year in its second quarter revenues.

For the three months ended June 30, revenues totaled DKK 30.7 million ($5.5 million), down from DKK 33.3 million in the year-ago period. The firm said research product sales and services declined 3 percent year over year to DKK 24.9 million in the quarter, while service revenues fell 10 percent to DKK 3.7 million.

Exiqon did not break out the rest of its revenues for the quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.